CA2172245A1 - Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein - Google Patents

Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein

Info

Publication number
CA2172245A1
CA2172245A1 CA 2172245 CA2172245A CA2172245A1 CA 2172245 A1 CA2172245 A1 CA 2172245A1 CA 2172245 CA2172245 CA 2172245 CA 2172245 A CA2172245 A CA 2172245A CA 2172245 A1 CA2172245 A1 CA 2172245A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
gram
negative
bacterial
antibiotic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2172245
Other languages
French (fr)
Other versions
CA2172245C (en )
Inventor
Jonathan Cohen
Ada H. C. Kung
Lewis H. Lambert, Jr.
Roger G. Ii Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XOMA Corp
Original Assignee
XOMA Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1712Not used, see subgroup
    • A61K38/1751Bactericidal/permeability-increasing protein [BPI]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742Bactericidal/Permeability-increasing protein [BPI]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis

Abstract

The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products.
Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
CA 2172245 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein Expired - Fee Related CA2172245C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12565193 true 1993-09-22 1993-09-22
US08/125,651 1993-09-22
US27340194 true 1994-07-11 1994-07-11
US08/273,401 1994-07-11
PCT/US1994/011225 WO1995008344A1 (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic

Publications (2)

Publication Number Publication Date
CA2172245A1 true true CA2172245A1 (en) 1995-03-30
CA2172245C CA2172245C (en) 2003-04-08

Family

ID=26823793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2172245 Expired - Fee Related CA2172245C (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein

Country Status (8)

Country Link
US (2) US5523288A (en)
EP (1) EP0759774B1 (en)
JP (1) JPH09502987A (en)
CA (1) CA2172245C (en)
DE (2) DE69430823D1 (en)
DK (1) DK0759774T3 (en)
ES (1) ES2178656T3 (en)
WO (1) WO1995008344A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
JPH09502987A (en) * 1993-09-22 1997-03-25 ゾーマ コーポレイション Bactericidal / permeability was improved (bpi) a method of treatment of gram-negative bacterial infection by administration of the protein product and antibiotics
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
EP0839156A1 (en) * 1995-07-20 1998-05-06 Xoma Corporation Anti-fungal peptides
WO1997026886A1 (en) * 1996-01-25 1997-07-31 Pharmacy And Therapeutic Advisory Consultancy Pty. Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
DE69703689D1 (en) * 1996-05-10 2001-01-18 Xoma Technology Ltd Therapeutic applications of BPI protein products for treatment of human meningococcämia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DE69719754D1 (en) * 1996-05-23 2003-04-17 Xoma Technology Ltd Therapeutic uses of BPI protein products in human trauma with bleeding caused by
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
CA2288457A1 (en) * 1997-05-02 1998-11-12 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999052357A1 (en) * 1998-04-14 1999-10-21 Ribogene, Inc. Assays for inhibitors of bacterial translation initiation factor 3
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US6696239B1 (en) * 2000-04-20 2004-02-24 Biolog, Inc. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
WO2002060879A3 (en) 2000-12-15 2003-03-27 Michael Badia Bacterial gyrase inhibitors and uses thereof
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
EP1421108A2 (en) 2001-08-24 2004-05-26 Dale Cameron Antimicrobial and anti-inflammatory peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
EP1585814B1 (en) * 2003-01-21 2014-05-07 Thallion Pharmaceuticals Inc. Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
EP1539962A4 (en) * 2003-09-11 2006-12-27 Ecopia Biosciences Inc Polyene polyketides and methods of production
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1741440A1 (en) * 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
US8871929B2 (en) 2010-08-03 2014-10-28 Merck Sharp & Dohme Corp. Fused-imidazoyl compounds useful as antimicrobial agents
WO2012097269A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Pyrimidine gyrase and topoisomerase iv inhibitors
US20120208744A1 (en) * 2011-02-16 2012-08-16 The Penn State Research Foundation Anti-microbial agents and compositions and methods of production and use thereof
US9125922B2 (en) 2011-06-20 2015-09-08 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2014026143A1 (en) * 2012-08-09 2014-02-13 Pono Corporation Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
WO2014160814A1 (en) * 2013-03-26 2014-10-02 Rutgers, The State University Of New Jersey Synthetic and enhanced bacterial killing involving bicyclomycin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028251A (en) * 1973-07-12 1975-03-22
JPS55134471A (en) * 1979-04-04 1980-10-20 Toshiba Corp Sales management system in small-scale computer constitution
CA1237671A (en) * 1983-08-01 1988-06-07 Elan Pharmaceuticals, Inc. Enhancement of pharmaceutical activity
JPH0218757B2 (en) * 1983-12-15 1990-04-26 Tokyo Electric Co Ltd
JPS619790A (en) * 1984-06-25 1986-01-17 Omron Tateisi Electronics Co Electronic cash register
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP0652230B1 (en) * 1987-08-11 2005-12-14 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
JP2774343B2 (en) * 1988-06-23 1998-07-09 アソシエイツ オブ ケイプ コード、インコーポレイテッド Endotoxin-binding protein and its use
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
DE69128968D1 (en) * 1990-12-03 1998-04-02 Univ New York Biologically active bactericidal / permeability-increasing protein bruchstücke
US5156665A (en) * 1991-01-03 1992-10-20 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes
JPH07502642A (en) * 1991-09-26 1995-03-23
WO1993023434A3 (en) * 1992-05-19 1994-01-06 Xoma Corp Bpi-immunoglobulin fusion proteins
WO1993023540A3 (en) * 1992-05-19 1994-01-20 Xoma Corp Improved methods for the preparation of endotoxin-binding proteins
CA2155005C (en) * 1993-02-02 1999-04-06 Weldon Courtney Mcgregor Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994020128A1 (en) * 1993-03-12 1994-09-15 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
DE69412243T2 (en) * 1993-03-12 1999-03-25 Xoma Corp Biologically active peptides from functional domains of Bactericidal / Permeability erhoehenden proteins and their use
DK0690721T3 (en) * 1993-03-12 1999-03-08 Xoma Corp Treatment of mycobacterial diseases by administration of bactericidal / permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
JPH09502987A (en) * 1993-09-22 1997-03-25 ゾーマ コーポレイション Bactericidal / permeability was improved (bpi) a method of treatment of gram-negative bacterial infection by administration of the protein product and antibiotics

Also Published As

Publication number Publication date Type
EP0759774B1 (en) 2002-06-12 grant
DK0759774T3 (en) 2002-10-07 grant
DE69430823D1 (en) 2002-07-18 grant
EP0759774A1 (en) 1997-03-05 application
JPH09502987A (en) 1997-03-25 application
DE69430823T2 (en) 2003-02-20 grant
US6140306A (en) 2000-10-31 grant
WO1995008344A1 (en) 1995-03-30 application
ES2178656T3 (en) 2003-01-01 grant
CA2172245C (en) 2003-04-08 grant
US5523288A (en) 1996-06-04 grant
DK759774T3 (en) grant

Similar Documents

Publication Publication Date Title
Smith et al. Use of gentamicin in combinations with other antibiotics
Carratalá et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin
Candiani et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Wade et al. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia
Brown Neutropenia, fever, and infection
Brown et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
Gentilini et al. Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis in Argentina
Rozenberg-Arska et al. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora
Farber et al. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics
Kruszewska et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model
Brook et al. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis
Harris et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa
Prescott et al. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
David et al. Bacterial infection and atopic eczema.
Lilenbaum et al. Prevalence and antimicrobial susceptibility of staphylococci isolated from the skin surface of clinically normal cats
Gan et al. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats
Cason et al. Mortality and infection in extensively burned patients treated with silver-nitrate compresses
Spížek et al. Lincomycin, clindamycin and their applications
Salmon et al. Minimum inhibitory concentrations for selected antimicrobial agents against organisms isolated from the mammary glands of dairy heifers in New Zealand and Denmark
Lorian Some effects of subinhibitory concentrations of antibiotics on bacteria.
Aarestrup Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin
Brook et al. Treatment of patients with a history of recurrent tonsillitis due to group A beta-hemolytic streptococci: A prospective randomized study comparing penicillin, erythromycin, and clindamycin
Taylor et al. Predominance of staphylococcal organisms in infections occurring in a burns intensive care unit
Burkhart et al. Microbiology's principle of biofilms as a major factor in the pathogenesis of acne vulgaris
Watanakunakorn Penicillin combined with gentamicin or streptomycin: synergism against enterococci

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed